July 2nd 2025
A new paper highlights Alphyn Biologics' Zabalafin Hydrogel as a promising multi-target therapy for atopic dermatitis, addressing inflammation, itch, and bacterial complications.
June 27th 2025
Quoin Pharmaceuticals advances QRX003 for Netherton Syndrome, receiving FDA's RPD Designation and showing promising clinical results.
Nektar Therapeutics reveals positive results from the REZOLVE-AD study, showcasing rezpegaldesleukin's efficacy in treating moderate to severe AD.
June 26th 2025
Galderma launches clinical trials for nemolizumab, targeting systemic sclerosis and chronic pruritus of unknown origin, addressing critical patient needs.
June 20th 2025
The new PDUFA date is set for September 2025.
FDA Approves Dupilumab, First and Only Targeted Medicine for Bullous Pemphigoid
Dupilumab gains FDA approval as the first targeted therapy for bullous pemphigoid, offering hope for effective treatment and improved patient outcomes.
Three-Year Data Reveals Long-Term Power of Bimekizumab for PsA
At the 2025 EULAR meeting, UCB presented new 3-year data on bimekizumab for PsA.
Targeted TYK2 Blockade for PsO Without JAK1/2/3 Impact
Zasocitinib emerges as a promising oral therapy for psoriasis and psoriatic arthritis, showcasing superior selectivity and safety compared to traditional JAK inhibitors.
Denifanstat Hits All Targets in Chinese Study
Sagimet Biosciences reveals denifanstat's promising phase 3 results, offering a novel oral treatment for moderate to severe acne with significant efficacy.
FDA Approves Arcutis’ Roflumilast Foam for Plaque Psoriasis
FDA approves Arcutis' roflumilast foam, a groundbreaking treatment for plaque psoriasis, offering a steroid-free, effective solution for patients aged 12 and older.
Quoin Receives FDA Clearance for Second Netherton Trial
Quoin Pharmaceuticals advances QRX003 for Netherton Syndrome, receiving FDA clearance for a pivotal trial to assess its effectiveness and safety.
AC-201 Shows Strong Phase 2 Results in Psoriasis Trial
Accropeutics reveals promising Phase 2 trial results for AC-201, a selective TYK2/JAK1 inhibitor, showing significant efficacy in treating plaque psoriasis.
Artax Presents Phase 2a Results of AX-158 for Plaque Psoriasis
The promising safety and efficacy results were presented at the Society for Investigative Dermatology 2025 Annual Meeting.
Corvus Pharmaceuticals’ Soquelitinib Shows Rapid, Dose-Dependent Efficacy in Phase 1 AD Trial
Selective ITK inhibition with oral soquelitinib led to early and durable clinical responses, cytokine reduction, and increased T regulatory cells.
FDA Approves First Gene Therapy for RDEB
The FDA approved pz-cel, a groundbreaking gene therapy for recessive dystrophic epidermolysis bullosa, transforming treatment options for patients.
FDA Approves Dupilumab for Adolescents and Adults With H1 Antihistamine-Refractory Chronic Spontaneous Urticaria
Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.
Hope on the Horizon: Expert Insights into Dupilumab for CSU
Having multiple therapeutic options would allow clinicians to tailor treatment and offer hope to patients who don't respond initially.
Exploring Off-Label Uses of Topical JAK Inhibitors
While approved for vitiligo and atopic dermatitis, ruxolitinib cream may help treat other inflammatory skin diseases.
Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates
Exclusive Q1 Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first quarter of 2025.
Quoin Files US Patent Applications for Rare Disease Treatments
The novel treatments will be for patients with orphan conditions like Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and palmoplantar keratoderma.
Potential Treatments for TSW Identified in NIH Study
A pilot study revealed that mitochondrial complex I-blocking drugs, like metformin and berberine, improved TSW symptoms in most participants.
L'Oréal Issues Voluntary Recall of Benzoyl Peroxide Products Over Benzene Concerns
The recall includes L'Oréal's Effaclar Duo product. Stay tuned for more updates throughout the day.
Medicus Reports Promising Interim Results for Non-Invasive BCC Treatment
Medicus’ previous phase 1 study confirmed D-MNA’s safety, with some participants achieving complete BCC clearance.
Almirall Showcases Therapeutic Innovations at AAD 2025
The company showcased advancements in tirbanibulin and its early-stage antibody LAD191.
New Study Explores Benzoyl Peroxide-Related Adverse Events and Potential Neoplasm Signals
Published in JID, the study analyzes data from the FDA’s FAERS database to examine cases of neoplasms—including skin and breast cancers—potentially associated with benzoyl peroxide use.
Journey Medical Publishes Full Phase 3 Trial Results for DFD-29
The findings of the MVOR-1 and MVOR-2 studies are published in JAMA Dermatology, supporting the rosacea drug’s recent FDA approval.
Edgar Charles, MD, on Long-term Deucravacitinib Psoriasis Data
Quoin Reports Positive QRX003 “Whole Body” Pediatric Data for Netherton Syndrome
After just 2 weeks of twice-daily use, a pediatric patient saw visually improved skin with no adverse events.
LEO Pharma Reports Positive Results in Delgocitinib Trial for CHE
DELTA China follows the success of European and Canadian trials, reinforcing delgocitinib’s potential as a global treatment for CHE.
FDA Accepts Supplemental New Drug Application for Arcutis’ Roflumilast in Children with AD
A PDUFA target action date has been set for October 13, 2025.
Current Clinical and Aesthetic Applications of Snail Mucin
Snail slime contains bioactive compounds that promote skin healing, hydration, and regeneration.
5-Year Study Backs Deucravacitinib’s Safety and Efficacy
The POETYK PSO LTE trial found deucravacitinib effective in sustaining PASI 75 and PASI 90 responses.
FDA Clears Zabalafin Hydrogel’s Investigational New Drug Application for AD
Alphyn’s therapy uniquely treats both the immune system and bacterial components of atopic dermatitis.
New Study Examines Connection Between Formulation and Benzene Levels in BPO Products
Barbieri et al evaluated product use, benzoyl peroxide concentration, days until expiration, and more.
Rezpegaldesleukin Receives Fast Track Designation for Moderate to Severe AD
Nektar Therapeutics’ investigational biologic targets the IL-2 receptor complex.
The Weekly Roundup: June 30-July 3
Dermatology Times Spot Test: July 3, 2025
The Future of Exoceuticals and Innovative Aesthetics, According to Robin Smith, MD, MBA
New Data Support Delgocitinib for Sensitive Skin Areas